| Issue Date | Title | Author(s) |
| 7-Jun-2017 | Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial | Chan, D; Binks, S; Nicholas, JM; Frost, C; Cardoso, MJ, et al |
| 15-Nov-2016 | Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis [version 1; peer review: 1 approved, 2 approved with reservations] | Lewin, A; Hamilton, S; Witkover, A; Langford, P; Nicholas, R, et al |
| 1-Sep-2015 | Hippocampal inflammation and depression in multiple sclerosis: integrating evidence from TSPO PET and resting state fMRI | Colasanti, A; Guo, Q; Giannetti, P; Wall, M; Newbould, RD, et al |
| 28-Jun-2016 | Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain | Feeney, C; Scott, G; Raffel, J; Roberts, S; Coello, C, et al |
| 21-Apr-2016 | Peripheral nerve dysfunction in middle-aged subjects born with thalidomide embryopathy | Nicholas, R; Nicotra, A; Newman, C; Johnson, M; Eremin, O, et al |
| 1-Sep-2015 | Positron emission tomography imaging in multiple sclerosis highlights a diffuse inflammatory response in brain that appears normal on conventional magnetic resonance imaging | Datta, G; Battaglini, M; Scott, G; Yaldizli, O; Ribeiro, AS, et al |